
Feature|Articles|February 18, 2026
- Pharmaceutical Executive: April 2026
- Volume 46
- Issue 3
From Sun Belt Boom to Biotech Hub: Why Southern Florida’s Moment has Arrived
Author(s)Daniel Teper, PharmD, MBA, Raquel Cabo
Greater Miami is rapidly emerging as an international biotech hot spot—as capital, talent, and infrastructure converge to transform the region from a tourism-driven economy into a globally connected life sciences innovation hub.
Advertisement
Advertisement
Southern Florida is experiencing one of the most significant economic transformations in the US. Once viewed primarily through the lens of tourism, wealth management, and sunshine-migration, the region is increasingly attracting some of the world’s most influential companies; it is a shift that reflects deep structural changes in how and where innovation chooses to cluster.
Related to this article

Eli Lilly breaks ground on a $3.5 billion manufacturing facility in Pennsylvania to produce next-generation obesity treatments like retatrutide.

As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.

FDA Commissioner’s National Priority Voucher program reportedly in limbo for expedited drug reviews.

Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.

Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.

Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.

Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.
Advertisement
Advertisement

